by Clinical Neuropsychologist Online | Wednesday, July 3, 2024 | Dementia
Abstract The Dominantly Inherited Alzheimer Network (DIAN) initially was funded by the National Institute on Aging (NIA) in 2008 and thus was able to adopt and incorporate the protocols developed by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) that had...
by Clinical Neuropsychologist Online | Wednesday, July 3, 2024 | Dementia
Abstract INTRODUCTION Cerebral blood flow (CBF) is reduced in cognitively impaired (CI) Alzheimer’s disease (AD) patients. We checked the sensitivity of time-encoded arterial spin labeling (te-ASL) in measuring CBF alterations in individuals with positive AD...
by Clinical Neuropsychologist Online | Wednesday, July 3, 2024 | Dementia
Abstract INTRODUCTION Mild cognitive impairment (MCI) is a prodromal stage of dementia. Understanding the mechanistic changes from healthy aging to MCI is critical for comprehending disease progression and enabling preventative intervention. METHODS Patients with MCI...
by Clinical Neuropsychologist Online | Wednesday, July 3, 2024 | Dementia
Abstract INTRODUCTION We examined the burden of neuropsychiatric symptoms (NPSs) in early-onset (EO) and late-onset (LO) Alzheimer’s disease (AD) and adjusted for age effects via the inclusion of cognitively unimpaired (CU) individuals. METHODS Cross-sectional...
by Clinical Neuropsychologist Online | Wednesday, July 3, 2024 | Dementia
Abstract INTRODUCTION Sodium-glucose cotransporter 2 (SGLT2) inhibitors exhibit potential benefits in reducing dementia risk, yet the optimal beneficiary subgroups remain uncertain. METHODS Individuals with type 2 diabetes (T2D) initiating either SGLT2 inhibitor or...
